Clinical trials: Scorpion Sting
- Condition Scorpion Sting
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Scorpion Envenomation
AScVS and/ or Prazosin for Scorpion Envenomation
The data available for the efficacy of AScVS and prazosin is generated through different trials done in different clinical setting.
- Trial name
- NCT00753064
- Testing
- Antiscorpion venom serum(AScVS)., T.Prazosin, AScVS + Prazosin
- Where
- 5 sites in India
- Volunteers
- 81 people
- Sponsor
- Haffkine Bio-Pharmaceutical Corporation Ltd.
Scorpion Sting Envenomation
Open Label Study of Alacramyn® in Pediatric Patients With Scorpion Sting Envenomation
There is no FDA approved therapy for the treatment of scorpion envenomation in the United States. Centruroides scorpion envenomation produces a pattern of neurotoxicity with a spectrum of severity ranging from trivial to life…
- Trial name
- NCT01599923
- Testing
- Antivenin Centruroides (scorpion) equine immune F(ab')2
- Where
- Mexico
- Volunteers
- 29 people
- Sponsor
- Instituto Bioclon S.A. de C.V.
Scorpion Sting
Open Label Clinical Trial of Anascorp® in Pediatric Patients With Scorpion Sting Envenomation
There is no FDA approved therapy for the treatment of scorpion envenomation. Centruroides scorpion envenomation produces a pattern of neurotoxicity with a spectrum of severity ranging from trivial to life threatening.
- Trial name
- NCT01599936
- Testing
- Anascorp
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Instituto Bioclon S.A. de C.V.
Poisoning by Scorpion Sting
A Trial of Equine F (ab')2 Antivenom for Treatment of Scorpion Envenomation in Morocco
This study has the objective to demonstrate the effectiveness of Alacramyn NAMO in the treatment of North Africa and Middle East scorpions envenomation by reducing the severity of envenomation.
- Trial name
- NCT01336660
- Testing
- Equine F(ab')2 antivenom
- Where
- 2 sites in Morocco
- Volunteers
- 56 people
- Sponsor
- Instituto Bioclon S.A. de C.V.
Scorpion Sting Envenomation
Treatment Protocol for Use of Anascorp™ in Patients With Scorpion Sting Envenomation
This treatment protocol will enable therapeutic use of Anascorp in the management of systemic manifestations of scorpion sting envenomation, in patients for whom antivenom would otherwise be unavailable.
- Trial name
- NCT00624078
- Testing
- Antivenin Centruroides (scorpion) F(ab)2 Anascorp™
- Where
- 18 sites in United States
- Volunteers
- 1,426 people
- Sponsor
- Instituto Bioclon S.A. de C.V.
Scorpion Sting Envenomation
Establishment of Natural History of Scorpion Envenomation
This retrospective study was conducted to collect data from approximately 100 patients from 6 months to 18 years of age who were stung by a scorpion but were not treated with antivenom.
- Trial name
- NCT00696683
- Testing
- None, this is an observational study
- Where
- United States
- Volunteers
- 97 people
- Sponsor
- Instituto Bioclon S.A. de C.V.
Scorpion Sting Envenomation
Double-Blind, Alacramyn® vs. Placebo in Pediatric Patients
There is no FDA approved therapy for the treatment of scorpion envenomation, Centruroides scorpion envenomation produces a pattern of neurotoxicity with a spectrum of severity ranging from trivial to life threatening.
- Trial name
- NCT00685230
- Testing
- Antivenin Centruroides (scorpion) equine immune F(ab)2
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Instituto Bioclon S.A. de C.V.